科研成果详情

题名UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
作者
发表日期2022-06-14
发表期刊FRONTIERS IN PHARMACOLOGY   影响因子和分区
语种英语
原始文献类型Article
关键词voxtalisib quantitative methodology pharmacokinetic analysis UPLC-MS MS technology rat plasma
其他关键词DUAL PI3K/MTOR INHIBITOR ; IN-VITRO ; SAFETY ; XL765
摘要

Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In this study, a highly sensitive and rapid ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technology was applied to the quantitative methodology and pharmacokinetic analysis of voxtalisib in rat plasma. After protein precipitation of the analyte by acetonitrile, the chromatographic separation was performed by gradient elution on an Acquity BEH C18 column (2.1 mm x 50 mm, 1.7 mu m) with acetonitrile (solvent A) and 0.1% formic acid (solvent B) as the mobile phase. In the positive ion mode, the mass transfer detection of the analyte and IS was m/z 270.91 > 242.98 and m/z 572.30 > 246.10, respectively. In the concentration range of 1-2000 ng/ml, a good linear relationship of voxtalisib was successfully established by the UPLC-MS/MS technology, and the lower limit of quantification (LLOQ) of the analyte was identified as 1 ng/ml. Intra-day and inter-day precisions for voxtalisib were 7.5-18.7% and 13.0-16.6%, respectively, and the accuracies were in the ranges of -14.0-2.0% and -7.2-3.1%, respectively. The matrix effect, extraction recovery, carryover and stability of the analyte were all in compliance with the acceptance criteria of bioassays recommended by FDA. Finally, the pharmacokinetic profile of the analyte had been availably studied by the UPLC-MS/MS bio-analytical method after rats were treated by intragastric administration with voxtalisib (5 mg/kg). The results indicated that the UPLC-MS/MS technology can effectively and quickly quantify the analyte, and this method can also be used for the pharmacokinetic study of voxtalisib, which can provide reference for the optimization of clinical drug management in the later period.

资助项目National Key Research and Development Program of China [2020YFC2008301] ; PhD Start-up Funds from The First Affiliated Hospital of Wenzhou Medical University [2022QD23]
出版者FRONTIERS MEDIA SA
出版地LAUSANNE
ISSN1663-9812
EISSN1663-9812
卷号13页码:914733
DOI10.3389/fphar.2022.914733
页数7
WOS类目Pharmacology & Pharmacy
WOS研究方向Pharmacology & Pharmacy
WOS记录号WOS:000817151300001
收录类别SCIE ; PUBMED ; SCOPUS
URL查看原文
PubMed ID35774599
SCOPUSEID2-s2.0-85133502822
通讯作者地址[Chen, Lianguo]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China ; [Shao, Liu]Chongqing University Cancer Hospital,Chongqing,China
Scopus学科分类Pharmacology;Pharmacology (medical)
引用统计
被引频次[WOS]:0   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/154524
专题附属第一医院
药学院(分析测试中心)_分子药理研究与教学中心
通讯作者Shao, Liu; Chen, Lianguo
作者单位
1.The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China;
2.Institute of Molecular Toxicology and Pharmacology,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,China;
3.Chongqing University Cancer Hospital,Chongqing,China
第一作者单位附属第一医院;  第一临床医学院(信息与工程学院)、附属第一医院;  药学院(分析测试中心)
通讯作者单位附属第一医院;  第一临床医学院(信息与工程学院)、附属第一医院
第一作者的第一单位附属第一医院
推荐引用方式
GB/T 7714
Li, Qingqing,Liu, Ya-Nan,Wang, Jing,et al. UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma[J]. FRONTIERS IN PHARMACOLOGY,2022,13:914733.
APA Li, Qingqing., Liu, Ya-Nan., Wang, Jing., Hu, Yingying., Hu, Jinyu., ... & Chen, Lianguo. (2022). UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma. FRONTIERS IN PHARMACOLOGY, 13, 914733.
MLA Li, Qingqing,et al."UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma".FRONTIERS IN PHARMACOLOGY 13(2022):914733.

条目包含的文件

下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Voxtalisib-Frontiers(1030KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览 下载
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Li, Qingqing]的文章
[Liu, Ya-Nan]的文章
[Wang, Jing]的文章
百度学术
百度学术中相似的文章
[Li, Qingqing]的文章
[Liu, Ya-Nan]的文章
[Wang, Jing]的文章
必应学术
必应学术中相似的文章
[Li, Qingqing]的文章
[Liu, Ya-Nan]的文章
[Wang, Jing]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Voxtalisib-Frontiers in Pharmacology.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。